Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics
1.00 hr(s) | CME , MOC , ABIM
Specialty: Ovarian Cancer
Therapeutic Area(s): Oncology
Release Date: July 21, 2020
Expiration Date: July 20, 2021
Location: Internet Activity Enduring
The advent of PARP inhibitors and precise selection of patients using companion diagnostics have improved outcomes for patients with advanced ovarian cancer and provided new opportunities for oncologists to individualize care. In this activity, based on a recent live webcast, a panel of leading experts discuss the rationale behind the use of PARP inhibition in ovarian cancer and how these agents and their companion diagnostics can be used in clinical practice in a variety of settings. Using case vignettes, the experts address real-world applications of the latest research, including how to prevent and manage adverse events associated with the use of PARP inhibitors and determine which patients may benefit from enrollment in clinical trials testing these agents alone or in combination with other treatments.